2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - Hall C
Technology and Procedures, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Gene Editing, Profiling, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Molecular Biology, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, MPN, CMML, Study Population, Human, Adult, Elderly
PAPER

101 SETBP1-mutant leukemias depend on MENIN-KMT2A chromatin complexes to maintain leukemogenic transcriptional programs

Samantha Tauchmann, PhD, Thai Nguyen, MS2, Hanqian Carlson, PhD3, Amara Pang, BS4, Theodore Paul Braun, MD PhD5, Julia Maxson, PhD6
1 Oregon Health and Science University, Portland, Oregon, United States
2 Oregon Health and Science University, Portland, Oregon, United States
3 Oregon Health and Science University, Portland, Oregon, United States
4 Oregon Health and Science University, Portland, Oregon, United States
5 Oregon Health and Science University, Portland, Oregon, United States
6 Oregon Health and Science University, Portland, Oregon, United States
SET binding protein 1 (SETBP1) is recurrently mutated in high-risk myeloid malignancies, including myelodysplastic/myeloproliferative overlap disorders, such as chronic myelomonocytic leukemia (CMML). These SETBP1 mutations, such as D868N, disrupt the degron motif to cause accumulation of mutant SETBP1 protein. Clinically, SETBP1 mutations are associated with adverse outcomes, including reduced overall survival, increased risk of relapse, and therapy resistance. Although SETBP1 mutations have been shown to promote self-renewal and activate HOX-driven transcriptional programs in murine and cell line models, the epigenetic dependencies sustaining these programs in human stem and progenitor cells (HSPCs) are incompletely defined.

To tackle this question, we first evaluated the effects of mutant SETBP1 in human HSPCs.  Expression of SETBP1D868N increases the growth of HSPCs in liquid culture. Interestingly, in colony-forming unit (CFU) assays, SETBP1D868N has minimal effects on colony number in the first plating but dramatically increases the serial replating potential of HSPCs. Transcriptional profiling revealed that mutant SETBP1 promotes HOXA/MEIS1-driven leukemogenic programs analogous to KMT2A-rearranged leukemias. To define the SETBP1 regulome in these cells, we profiled its occupancy using CUT&Tag. Integration of gene expression with chromatin occupancy using BETA2 identified a high-confidence SETBP1 regulome comprising 113 genes that were both significantly upregulated and directly bound by SETBP1. Notably, these targets include key leukemogenic regulators such as HOXA9, MEIS1, MECOM, and MYB and were significantly enriched for transcriptional programs associated with KMT2A-rearranged, NUP98-HOXA9, and NPM1-mutant leukemias. These findings demonstrate that mutant SETBP1 establishes a stem cell-like leukemogenic regulome through engagement of KMT2A-associated transcriptional networks.

In addition to binding to KMT2A-associated genes, SETBP1 is known to interact with KMT2 methyltransferase complex members, including KMT2A, KMT2B, and DOT1L. To evaluate whether SETBP1D868N HSPCs are dependent on these interactors, we harnessed CRISPR-Cas9-mediated knockout. Loss of KMT2A markedly impaired proliferation, whereas disruption of KMT2B or DOT1L had no significant effect. We also assessed the essentiality of the key KMT2A cofactor, MEN1. Deletion of MEN1 phenocopied KMT2A loss, without affecting control HSPCs, indicating a specific dependency on the KMT2A-MENIN complex. RNA sequencing revealed that KMT2A loss suppressed canonical SETBP1-driven transcriptional programs, including HOXA cluster genes, MEIS1, MECOM, MYB and MYC, as well as leukemia stem cell-associated genes. Consistent with loss of progenitor identity, stem cell markers were downregulated. Disruption of MEN1 similarly attenuated key leukemogenic transcriptional programs. This suggests a shared mechanism of regulation through the KMT2A-MENIN axis.

Next, to understand the therapeutic relevance of these findings, we evaluated whether inhibitors of the KMT2A-MENIN interaction would also interrupt SETBP1-driven oncogenesis. In a SETBP1-mutant cell line (MOLM-20), ziftomenib reduced the expression of canonical SETBP1 target genes, including HOXA9, MEIS1, and MECOM. In primary human CD34+ cells expressing SETBP1D868N, menin inhibition abrogated the enhanced self-renewal observed upon serial replating. Ongoing studies are evaluating the effects of KMT2A:MENIN inhibition on SETBP1 and KMT2A complex chromatin occupancy in human HSPCs.


To extend these findings to clinically relevant models, we evaluated the effects of menin inhibitors on five leukemia patient samples harboring SETBP1 mutations within the degron motif (D868N, G870S). Treatment with ziftomenib, revumenib, or bleximenib significantly reduced clonogenic output in SETBP1-mutant leukemia samples. Notably, menin inhibition induced myeloid differentiation, as shown by increased CD11b and CD15 marker expression. Canonical SETBP1 target genes, including HOXA9, HOXA10 and MECOM, were significantly downregulated upon treatment.

Together, these findings identify the KMT2A-MENIN complex as a selective dependency in SETBP1-mutant leukemias and demonstrate that disruption of this axis suppresses leukemogenic transcriptional programs while promoting myeloid differentiation. The disruption of the MENIN-KMT2A interaction presents a promising therapeutic strategy to target epigenetic vulnerabilities in SETBP1-mutant leukemias.
Samantha Tauchmann, PhD: No relevant conflicts of interest to declare.